Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913260 · ClinicalTrials.gov registry record · Phase 1
A Study of Different Injectable Formulations of LY3375880 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT03913260 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 83 participants.
The verdict
NCT03913260, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The main purposes of this study are: 1. To learn more about the safety and side effects of different formulations of LY3375880 and 2. To measure how much LY3375880 gets into the blood stream and how long it takes to get out of the body. The study will last about 85 days. Screening may occur up to 28 days prior to enrollment.
Interventions
- DEVICE Autoinjector (AI)
- DRUG LY3375880
- DRUG Buffer Matrix (No LY3375880)
- DEVICE Manual Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03913260
The ClinicalTrials.gov registry entry for NCT03913260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Autoinjector (AI) is the first listed.
NCT03913260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03913260 about?
NCT03913260 is a clinical study titled "A Study of Different Injectable Formulations of LY3375880 in Healthy Participants". The main purposes of this study are: 1. To learn more about the safety and side effects of different formulations of LY3375880 and 2. To measure how much LY3375880 gets into the blood stream and how long it takes to get out of the body. The study will last about 85 days. Screening may occur up to 28...
What is the current status of trial NCT03913260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2019-05-01. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT03913260?
The interventions under investigation include: Autoinjector (AI) (DEVICE), LY3375880 (DRUG), Buffer Matrix (No LY3375880) (DRUG), Manual Syringe (DEVICE).
Who is sponsoring clinical trial NCT03913260?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.